# Niagen Bioscience, Inc.: financial statements, quarterly

NAGE · Nasdaq · CIK 1386570 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nage.md) · [Financials](/companies/nage/financials.md) · [Filings](/companies/nage/filings.md) · [Insiders](/companies/nage/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nage/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.5](/filings/0001628280-24-044540.md) | [21.2 d](/filings/0001628280-25-009774.md) | [22.2](/filings/0001628280-25-023127.md) | [22.7](/filings/0001386570-25-000010.md) | [25.6](/filings/0001386570-25-000020.md) | [29.1 d](/filings/0001386570-26-000013.md) | [30.5](/filings/0001386570-26-000030.md) | [31.1](/filings/0001386570-26-000043.md) | [34.0](/filings/0001386570-25-000020.md) | [33.8 d](/filings/0001386570-26-000013.md) | [31.5](/filings/0001386570-26-000030.md) | [29.8](/filings/0001386570-26-000043.md) |
| Cost of revenue | $m | [7.5](/filings/0001628280-24-044540.md) | [8.3 d](/filings/0001628280-25-009774.md) | [8.7](/filings/0001628280-25-023127.md) | [9.0](/filings/0001386570-25-000010.md) | [9.3](/filings/0001386570-25-000020.md) | [10.9 d](/filings/0001386570-26-000013.md) | [11.2](/filings/0001386570-26-000030.md) | [10.9](/filings/0001386570-26-000043.md) | [12.1](/filings/0001386570-25-000020.md) | [12.1 d](/filings/0001386570-26-000013.md) | [11.5](/filings/0001386570-26-000030.md) | [10.5](/filings/0001386570-26-000043.md) |
| Gross profit | $m | [12.0](/filings/0001628280-24-044540.md) | [12.9 d](/filings/0001628280-25-009774.md) | [13.5](/filings/0001628280-25-023127.md) | [13.7](/filings/0001386570-25-000010.md) | [16.2](/filings/0001386570-25-000020.md) | [18.2 d](/filings/0001386570-26-000013.md) | [19.3](/filings/0001386570-26-000030.md) | [20.2](/filings/0001386570-26-000043.md) | [21.9](/filings/0001386570-25-000020.md) | [21.7 d](/filings/0001386570-26-000013.md) | [20.0](/filings/0001386570-26-000030.md) | [19.3](/filings/0001386570-26-000043.md) |
| Research and development | $m | [1.2](/filings/0001628280-24-044540.md) | [1.2 d](/filings/0001628280-25-009774.md) | [2.1](/filings/0001628280-25-023127.md) | [1.3](/filings/0001386570-25-000010.md) | [1.3](/filings/0001386570-25-000020.md) | [1.3 d](/filings/0001386570-26-000013.md) | [1.3](/filings/0001386570-26-000030.md) | [1.6](/filings/0001386570-26-000043.md) | [1.8](/filings/0001386570-25-000020.md) | [1.7 d](/filings/0001386570-26-000013.md) | [1.5](/filings/0001386570-26-000030.md) | [1.5](/filings/0001386570-26-000043.md) |
| Operating income | $m | [(1.1)](/filings/0001628280-24-044540.md) | [(0.2) d](/filings/0001628280-25-009774.md) | [(0.7)](/filings/0001628280-25-023127.md) | [(0.3)](/filings/0001386570-25-000010.md) | [1.6](/filings/0001386570-25-000020.md) | [7.1 d](/filings/0001386570-26-000013.md) | [4.8](/filings/0001386570-26-000030.md) | [3.2](/filings/0001386570-26-000043.md) | [4.2](/filings/0001386570-25-000020.md) | [4.1 d](/filings/0001386570-26-000013.md) | [1.6](/filings/0001386570-26-000030.md) | [0.7](/filings/0001386570-26-000043.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001628280-25-023127.md) | [0.0](/filings/0001386570-25-000010.md) | [0.0](/filings/0001386570-25-000020.md) | [0.3 d](/filings/0001386570-26-000013.md) | [0.2](/filings/0001386570-26-000030.md) | [0.1](/filings/0001386570-26-000043.md) | [0.2](/filings/0001386570-25-000020.md) | [0.3 d](/filings/0001386570-26-000013.md) | [0.4](/filings/0001386570-26-000030.md) | [0.1](/filings/0001386570-26-000043.md) |
| Net income | $m | [(1.0)](/filings/0001628280-24-044540.md) | [0.1 d](/filings/0001628280-25-009774.md) | [(0.5)](/filings/0001628280-25-023127.md) | [(0.0)](/filings/0001386570-25-000010.md) | [1.9](/filings/0001386570-25-000020.md) | [7.2 d](/filings/0001386570-26-000013.md) | [5.1](/filings/0001386570-26-000030.md) | [3.6](/filings/0001386570-26-000043.md) | [4.6](/filings/0001386570-25-000020.md) | [4.1 d](/filings/0001386570-26-000013.md) | [6.3](/filings/0001386570-26-000030.md) | [1.0](/filings/0001386570-26-000043.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001628280-24-044540.md) | not reported | [(0.01)](/filings/0001628280-25-023127.md) | [0.00](/filings/0001386570-25-000010.md) | [0.02](/filings/0001386570-25-000020.md) | not reported | [0.06](/filings/0001386570-26-000030.md) | [0.04](/filings/0001386570-26-000043.md) | [0.05](/filings/0001386570-25-000020.md) | not reported | [0.07](/filings/0001386570-26-000030.md) | [0.01](/filings/0001386570-26-000043.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001628280-24-044540.md) | not reported | [(0.01)](/filings/0001628280-25-023127.md) | [0.00](/filings/0001386570-25-000010.md) | [0.02](/filings/0001386570-25-000020.md) | not reported | [0.07](/filings/0001386570-26-000030.md) | [0.05](/filings/0001386570-26-000043.md) | [0.06](/filings/0001386570-25-000020.md) | not reported | [0.08](/filings/0001386570-26-000030.md) | [0.01](/filings/0001386570-26-000043.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.6](/filings/0001628280-23-037809.md) | [27.2](/filings/0001628280-24-009380.md) | [27.4](/filings/0001628280-24-021645.md) | [27.7](/filings/0001628280-24-035591.md) | [32.2](/filings/0001628280-24-044540.md) | [44.5](/filings/0001628280-25-009774.md) | [55.5](/filings/0001628280-25-023127.md) | [60.3](/filings/0001386570-25-000010.md) | [64.1](/filings/0001386570-25-000020.md) | not reported | not reported | not reported |
| Current assets | $m | [47.2](/filings/0001628280-23-037809.md) | [49.5](/filings/0001628280-25-009774.md) | [49.0](/filings/0001628280-24-021645.md) | [49.3](/filings/0001628280-24-035591.md) | [52.1](/filings/0001628280-24-044540.md) | [64.1](/filings/0001386570-26-000013.md) | [76.2](/filings/0001628280-25-023127.md) | [86.7](/filings/0001386570-25-000010.md) | [93.6](/filings/0001386570-25-000020.md) | [96.8](/filings/0001386570-26-000043.md) | [105](/filings/0001386570-26-000030.md) | [97.8](/filings/0001386570-26-000043.md) |
| Total assets | $m | [53.5](/filings/0001628280-23-037809.md) | [55.0](/filings/0001628280-25-009774.md) | [54.1](/filings/0001628280-24-021645.md) | [54.0](/filings/0001628280-24-035591.md) | [56.5](/filings/0001628280-24-044540.md) | [68.3](/filings/0001386570-26-000013.md) | [81.3](/filings/0001628280-25-023127.md) | [91.5](/filings/0001386570-25-000010.md) | [98.1](/filings/0001386570-25-000020.md) | [106](/filings/0001386570-26-000043.md) | [114](/filings/0001386570-26-000030.md) | [107](/filings/0001386570-26-000043.md) |
| Current liabilities | $m | [19.4](/filings/0001628280-23-037809.md) | [20.6](/filings/0001628280-25-009774.md) | [19.5](/filings/0001628280-24-021645.md) | [17.9](/filings/0001628280-24-035591.md) | [17.7](/filings/0001628280-24-044540.md) | [17.9](/filings/0001386570-26-000013.md) | [20.8](/filings/0001628280-25-023127.md) | [22.3](/filings/0001386570-25-000010.md) | [22.7](/filings/0001386570-25-000020.md) | [19.9](/filings/0001386570-26-000043.md) | [22.8](/filings/0001386570-26-000030.md) | [15.1](/filings/0001386570-26-000043.md) |
| Total liabilities | $m | [26.2](/filings/0001628280-23-037809.md) | [26.5](/filings/0001628280-25-009774.md) | [25.1](/filings/0001628280-24-021645.md) | [23.3](/filings/0001628280-24-035591.md) | [22.2](/filings/0001628280-24-044540.md) | [22.2](/filings/0001386570-26-000013.md) | [26.0](/filings/0001628280-25-023127.md) | [27.3](/filings/0001386570-25-000010.md) | [27.5](/filings/0001386570-25-000020.md) | [29.9](/filings/0001386570-26-000043.md) | [32.0](/filings/0001386570-26-000030.md) | [24.1](/filings/0001386570-26-000043.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [27.3](/filings/0001628280-24-044540.md) | [28.5](/filings/0001386570-26-000013.md) | [29.0](/filings/0001386570-25-000010.md) | [30.7](/filings/0001386570-25-000020.md) | [34.4](/filings/0001386570-25-000020.md) | [46.1](/filings/0001386570-26-000043.md) | [55.3](/filings/0001386570-26-000043.md) | [64.2](/filings/0001386570-26-000043.md) | [70.7](/filings/0001386570-25-000020.md) | [76.5](/filings/0001386570-26-000043.md) | [82.3](/filings/0001386570-26-000043.md) | [82.5](/filings/0001386570-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [396 d](/filings/0001628280-24-044540.md) | [649 d](/filings/0001628280-25-009774.md) | [295](/filings/0001628280-25-023127.md) | [(264) d](/filings/0001386570-25-000010.md) | [3,495 d](/filings/0001386570-25-000020.md) | [8,583 d](/filings/0001386570-26-000013.md) | [7,883](/filings/0001386570-26-000030.md) | [1,250 d](/filings/0001386570-26-000043.md) | [3,692 d](/filings/0001386570-25-000020.md) | [679 d](/filings/0001386570-26-000013.md) | [(1,194)](/filings/0001386570-26-000030.md) | [2,772 d](/filings/0001386570-26-000043.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001386570-26-000030.md) | [0.0 d](/filings/0001386570-26-000043.md) | not reported | not reported | [2,354](/filings/0001386570-26-000030.md) | [2,767 d](/filings/0001386570-26-000043.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [68.3](/filings/0001628280-23-037809.md) | [74.8](/filings/0001628280-24-021645.md) | [75.0](/filings/0001628280-24-035591.md) | [75.1](/filings/0001628280-24-044540.md) | [75.2](/filings/0001628280-25-023127.md) | [75.6](/filings/0001386570-25-000010.md) | [77.8](/filings/0001386570-25-000020.md) | [83.2](/filings/0001386570-26-000030.md) | [86.2](/filings/0001386570-26-000043.md) | [86.6](/filings/0001386570-25-000020.md) | [84.6](/filings/0001386570-26-000030.md) | [82.5](/filings/0001386570-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 79,126,002 at 2026-07-30, from the cover of the [10-Q filed 2026-08-04](/filings/0001386570-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.